Acelyrin (NASDAQ:SLRN – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($ ...

Is it a “poison pill” aimed at torpedoing the entire deal? Is it Russia pushing maximalist negotiating positions, similar to what it’s done since before the start of the all-out invasion of ...

Such shareholder rights plans, sometimes called “poison pills,” are used by publicly traded companies to fend off takeovers. Lee’s would trigger if an entity accumulated 15% of its stock.

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

Acelyrin, Inc. (NASDAQ: SLRN), relating to the proposed merger with Alumis Inc. Under the terms of the agreement, Acelyrin stockholders will receive 0.4274 shares of Alumis common stock per share ...

In a report released today, Terry Ma from Barclays maintained a Buy rating on Air Lease (AL – Research Report), with a price target of $56.00. The company’s shares closed yesterday at $49.50 ...

A DIY injection could soon grant women long-term protection from pregnancy without the need for procedures or pills. The jab, developed by US scientists, contains microscopic crystals that ...

Ukrainian presidential communications advisor Dmytro Lytvyn reacted sharply on X to the Russian proposal for a transitional administration, writing that Putin needed to take some pills to kickstart ...

As a daily pill-taker, I’ve learned that the phrase “Out of sight, out of mind” holds all too true when it comes to staying on top of my medications. A pill case that looks and feels nice ...

Immune-mediated disease specialist Alumis is currently in the process of buying Acelyrin. Alumis’ pipeline is headed up by ESK-001, with the company sharing phase 2 data a year ago that showed ...

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 ...